FDA clears AZ’s new PNH therapy Voydeya

April 1, 2024


Voydeya (danicopan) can now be used as add-on therapy to AZ’s complement C5 inhibitors Ultomiris (ravulizumab) or Soliris (eculizumab) to treat extravascular haemolysis (EVH) in adults with PNH who don’t get a satisfactory response from the C5 drugs on their own.

In PNH, the body’s complement system destroys red blood cells, leading to anaemia and fatigue and, in some cases, patients need regular blood transfusions. It is estimated that somewhere between 10% and 20% of PNH patients still experience EVH while on treatment with Ultomiris or Soliris, which are currently the standard of care and administered by intravenous infusion.

Read More on Pharmaphorum